Denmark Antifungal Drugs Market Size & Outlook, 2023-2030
Denmark antifungal drugs market, 2018-2030 (US$M)
Related Markets
Denmark antifungal drugs market highlights
- The Denmark antifungal drugs market generated a revenue of USD 106.0 million in 2023 and is expected to reach USD 139.5 million by 2030.
- The Denmark market is expected to grow at a CAGR of 4% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 106.0 million |
| Market revenue in 2030 | USD 139.5 million |
| Growth rate | 4% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Denmark accounted for 0.7% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.55% in 2023. Horizon Databook has segmented the Denmark antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Strategic initiatives by local players are expected to boost market growth in the country. For instance, in May 2022, Denmark-based Novo Holdings A/S announced that F2G Ltd. (F2G) (Novo Holdings A/S' portfolio company) entered into a collaboration with Shionogi & Co., Ltd. for the development and commercialization of olorofim, an antifungal agent for the treatment of invasive fungal infections.
Such strategic moves by companies in the country are expected to boost market growth.The Danish Health and Medicines Authority is the main authority in healthcare and regulatory control of pharmaceutical products.
It ensures the availability of safe and effective pharmaceutical products, new therapies, and medical devices, promoting their proper use. The Danish Medicine Act is responsible for conducting clinical trials on medicinal products under section 88 of the Danish Medicines Act.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Denmark antifungal drugs market size, by drug class, 2018-2030 (US$M)
Denmark Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
